Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects

Journal of Diabetes Investigation

Volumn 2, Issue 3, 2011, Pages 193-199

  Harada, Norio ^a   Hamasaki, Akihiro ^a   Yamane, Shunsuke ^a   Muraoka, Atsushi ^a   Joo, Erina ^a   Fujita, Kazuyo ^a   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Gastric inhibitory polypeptide; Glucagon like peptide 1; Incretin

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INSULIN RELEASE; INSULIN SENSITIVITY; JAPANESE; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

EID: 79961078408     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00078.x     Document Type: Article

References (45)

1. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
2. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormone: similalities and differernce. J Diabetes Invest 2010; 1: 8-23.
3. Drucker DJ. The biology of incretin hormones. Cell Metab 2010; 3: 153-165.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
5. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 2: 22-29.
6. Haffner SM, Stern MP, Hazuda HP, et al. Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 1988; 17: 1297-1301.
7. Saad MF, Knowler WC, Pettitt D, et al. A two-step model for development of non-insulin-dependent diabetes. Am J Med 1991; 90: 229-235.
8. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
9. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
10. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
11. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 1997; 40: 984-986.
12. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843-14847.
13. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
14. Flatt PR, Bailey CJ, Kwasowski P, et al. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 1983; 32: 433-435.
15. Creuzfeldt W, Ebert R, Willms B, et al. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 1978; 14: 15-24.
16. Harada N, Yamada Y, Tsukiyama K, et al. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic betacells in obese mice. Am J Physiol Endocrinol Metab 2008; 294: E61-E68.
17. Vilsbøll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609- 613.
18. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687.
19. Faerch K, Vaag A, Holst JJ, et al. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008; 51: 853-861.
20. Yabe D, Kuroe A, Lee S, et al. Little enhancement of mealinduced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 2010; 1: 56-59.
21. Chiu KC, Chuang LM, Yoon C. Comparison of measured and estimated indices of insulin sensitivity and beta cell function: impact of ethnicity on insulin sensitivity and beta cell function in glucose-tolerant and normotensive subjects. J Clin Endocrinol Metab 2001; 86: 1620-1625.
22. Mandavilli A, Cyranoski D. Asian's big problem. Nature Med 2004; 10: 325-327.
23. Seino Y, Ikeda M, Yawata M, et al. The insulinogenic index in secondary diabetes. Horm Metab Res 1975; 7: 323-335.
24. Harada N, Fukushima M, Toyoda K, et al. Factors responsible for elevation of one hour postchallenge plasma glucose levels in Japanese men. Diabetes Res Clin Pract 2008; 81: 284- 289.
25. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
26. Alberi KG, Zimmeret PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 54: 539- 553.
27. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009; 26: 187-188.
28. Lim GE, Huang GJ, Flora N, et al. Insulin regulates glucagonlike peptide-1 secretion from the enteroendocrine L cell. Endocrinology 2009; 150: 580-591.
29. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
30. Fukushima M, Taniguchi A, Sakai M, et al. Homeostasis model assessment as a clinical index of insulin resistance. Diabetes Care 1999; 22: 1911-1912.
31. Matsuda M, Defronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euroglycemic insulin clamp. Diabetes Care 1999; 22: 1462- 1470.
32. Seltzer HS, Allen EW, Herron AL Jr, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967; 46: 323-335.
33. Rabinowitz D, Zierler KL. Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism. J Clin Invest 1962; 41: 2173-2181.
34. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
35. Kozawa J, Okita K, Imagawa A, et al. Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem Biophys Res Commun 2010; 393: 410-413.
36. Lee S, Yabe D, Nohtomi K, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2009; 57: 119-126.
37. Wishart JM, Horowitz M, Morris HA, et al. Relation between gastric empting of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 1998; 19: 1049-1053.
38. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113: 1582-1588.
39. Suzuki H, Fukushima M, Usami M, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes care 2003; 26: 1211- 1215.
40. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
41. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
42. Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 81: 161- 168.
43. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 79: 291-298.
44. Mitsui R, Fukushima M, Nishi Y, et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism 2006; 55: 53-58.
45. Saxena R, Hivert M, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142- 148.